Fernández-de-Las-Peñas César, Guijarro Carlos, Velasco-Arribas María, Torres-Macho Juan, Franco-Moreno Ana, Truini Andrea, Pellicer-Valero Oscar, Arendt-Nielsen Lars
Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid, Spain.
Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark.
Front Med (Lausanne). 2023 Nov 28;10:1301970. doi: 10.3389/fmed.2023.1301970. eCollection 2023.
Evidence suggests that individuals who had survived to coronavirus disease, 2019 (COVID-19) could develop neuropathic post-COVID pain. This study investigated the association of serological biomarkers and treatments received during hospitalization with development of neuropathic-associated symptoms.
One hundred and eighty-three ( = 183) previously hospitalized COVID-19 survivors during the first wave of the pandemic were assessed in a face-to-face interview 9.4 months after hospitalization. Nineteen serological biomarkers, hospitalization data, and treatment during hospitalization were obtained from medical records. Neuropathic pain symptoms (Self-Report Leeds Assessment of Neuropathic Scale), sleep quality (Pittsburgh Sleep Quality Index), pain catastrophizing (Pain Catastrophizing Scale) and anxiety/depressive levels (Hospital Anxiety and Depression Scale) were assessed.
The prevalence of post-COVID pain was 40.9% ( = 75). Fifteen (20%) patients reported neuropathic symptoms. Overall, no differences in hospitalization data and serological biomarkers were identified according to the presence or not of neuropathic-associated symptoms. Patients with post-COVID pain had the highest neutrophil count, and analysis revealed that patients with neuropathic post-COVID associated symptoms had lower neutrophil count ( = 0.04) compared with those without neuropathic pain, but differences were small and possible not clinically relevant. No differences in fatigue, dyspnea, brain fog, anxiety or depressive levels, poor sleep, or pain catastrophism between patients with and without neuropathic symptoms were found.
It seems that neuropathic-like post-COVID pain symptoms are not associated with neither of assessed serological biomarkers at hospital admission nor hospitalization treatments received in this cohort of hospitalized COVID-19 survivors.
有证据表明，2019冠状病毒病（COVID-19）幸存者可能会出现新冠后神经性疼痛。本研究调查了血清生物标志物以及住院期间接受的治疗与神经性相关症状发生之间的关联。
在大流行第一波期间曾住院的183名COVID-19幸存者在出院9.4个月后接受了面对面访谈。从病历中获取了19种血清生物标志物、住院数据以及住院期间的治疗情况。评估了神经性疼痛症状（利兹神经性疼痛自评量表）、睡眠质量（匹兹堡睡眠质量指数）、疼痛灾难化（疼痛灾难化量表）以及焦虑/抑郁水平（医院焦虑抑郁量表）。
新冠后疼痛的患病率为40.9%（n = 75）。15名（20%）患者报告有神经性症状。总体而言，根据是否存在神经性相关症状，未发现住院数据和血清生物标志物存在差异。新冠后疼痛患者的中性粒细胞计数最高，分析显示，与无神经性疼痛的患者相比，有新冠后神经性相关症状的患者中性粒细胞计数较低（P = 0.04），但差异较小，可能无临床意义。有神经性症状和无神经性症状的患者在疲劳、呼吸困难、脑雾、焦虑或抑郁水平、睡眠不佳或疼痛灾难化方面均未发现差异。
在这组住院的COVID-19幸存者中，似乎新冠后类似神经性疼痛的症状与入院时评估的血清生物标志物以及住院治疗均无关联。
